0.03
—
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Invion
Its shares trade on ASX under the ticker IVX.AX. It has been listed since 15 December 2009. In the fiscal year to 30 June 2025, it reported a net loss of A$8.8m. At that date it held total assets of A$9.5m and shareholders' equity of A$8.3m.
Invion Ltd. is a clinical-stage life sciences company, which engages in the research and development of treatments for market opportunities in a variety of cancer indications, chronic inflammatory, and autoimmune diseases. The company is headquartered in Melbourne, Victoria. The company went IPO on 2009-12-15. The firm is engaged in the completion of clinical development programs and targeted business development programs associated with its approximately three drug assets, such as INV102 (nadolol), INV103 (ala-Cpn10) and INV104 (zafirlukast). The company focuses on the development of treatments for opportunities in chronic inflammatory and respiratory disease. INV102 (nadolol) is a beta adrenergic biased ligand targeted to treat chronic inflammatory airway diseases via the reversal of mucous metaplasia in the airway epithelium. INV104 (zafirlukast) is a leukotriene receptor antagonist (LTRA) that reduces inflammation, constriction of the airways, and the build-up of mucus in the lungs. INV103 (ala-Cpn10) is a modified, naturally occurring human protein, which has been proposed as a founding member of the Resolution Associated Molecular Pattern (RAMPs) family hypothesized to maintain and restore immune homeostasis.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 15 Dec 2009
- Employees
- 8
- Website
- inviongroup.com ↗
Leadership
Pay as last reported
- Mr. Thian ChewExecutive Chairman of the Board, Chief Executive Officer, since 2017A$1.5m
- Ms. Melanie LeydinCompany Secretary, since 2020
- Mr. Alistair BennallackNon-Executive DirectorA$54,740
- Mr. Alan YamashitaNon-Executive DirectorA$76,287
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Invion Ltd has a diverse product portfolio, offering a range of innovative and effective solutions in various industries.
- The company has a strong intellectual property portfolio and a team of experts with extensive knowledge and expertise.
- Invion Ltd has established strategic partnerships and collaborations, allowing access to additional resources and opportunities for growth.
Weaknesses
- The company is relatively small compared to some of its competitors, limiting its financial resources and market reach.
- Invion Ltd may face challenges in terms of scalability and production capabilities as it expands its operations.
- There might be a certain level of customer perception regarding the company's brand and reputation due to its size and market presence.
Opportunities
- The growing demand for innovative solutions presents significant opportunities for Invion Ltd to expand its market share.
- The company can leverage advancements in technology and research to develop new and improved products.
- Exploring international markets and partnerships can help Invion Ltd tap into new customer segments and increase global presence.
Threats
- Fluctuating economic conditions and market uncertainties may impact the demand for Invion Ltd's products.
- Competitors with larger market shares and greater resources pose a threat to Invion Ltd's market position and growth prospects.
- Regulatory changes and compliance requirements in the industries Invion Ltd operates in can create challenges and constraints.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.